My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 101

    1.

    Protein engineering strategies for sustained glucagon-like peptide-1 receptor-dependent control of glucose homeostasis.

    Picha KM, Cunningham MR, Drucker DJ, Mathur A, Ort T, Scully M, Soderman A, Spinka-Doms T, Stojanovic-Susulic V, Thomas BA, O'Neil KT.

    Diabetes. 2008 Jul;57(7):1926-34. Epub 2008 Apr 21.PMID: 18426860 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    CNTO736, a novel glucagon-like peptide-1 receptor agonist, ameliorates insulin resistance and inhibits very low-density lipoprotein production in high-fat-fed mice.

    Parlevliet ET, Schröder-van der Elst JP, Corssmit EP, Picha K, O'Neil K, Stojanovic-Susulic V, Ort T, Havekes LM, Romijn JA, Pijl H.

    J Pharmacol Exp Ther. 2009 Jan;328(1):240-8. Epub 2008 Oct 10.PMID: 18849357 [PubMed - indexed for MEDLINE]Related articles

    3.

    Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo.

    Baggio LL, Kim JG, Drucker DJ.

    Diabetes. 2004 Dec;53 Suppl 3:S205-14.PMID: 15561912 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.

    Baggio LL, Huang Q, Brown TJ, Drucker DJ.

    Gastroenterology. 2004 Aug;127(2):546-58.PMID: 15300587 [PubMed - indexed for MEDLINE]Related articles

    5.

    An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis.

    Baggio LL, Huang Q, Cao X, Drucker DJ.

    Gastroenterology. 2008 Apr;134(4):1137-47. Epub 2008 Jan 11.PMID: 18313669 [PubMed - indexed for MEDLINE]Related articles

    6.

    The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice.

    Maida A, Lovshin JA, Baggio LL, Drucker DJ.

    Endocrinology. 2008 Nov;149(11):5670-8. Epub 2008 Jul 31.PMID: 18669601 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.

    Baggio LL, Huang Q, Brown TJ, Drucker DJ.

    Diabetes. 2004 Sep;53(9):2492-500.PMID: 15331566 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.

    Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, Du X, Petrov A, Lassman ME, Jiang G, Liu F, Miller C, Tota LM, Zhou G, Zhang X, Sountis MM, Santoprete A, Capito' E, Chicchi GG, Thornberry N, Bianchi E, Pessi A, Marsh DJ, SinhaRoy R.

    Diabetes. 2009 Oct;58(10):2258-66. Epub 2009 Jul 14.PMID: 19602537 [PubMed - indexed for MEDLINE]Related articles

    9.

    Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling.

    Scrocchi LA, Marshall BA, Cook SM, Brubaker PL, Drucker DJ.

    Diabetes. 1998 Apr;47(4):632-9.PMID: 9568697 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Glucagon-like peptide (GLP)-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling.

    Lovshin J, Estall J, Yusta B, Brown TJ, Drucker DJ.

    J Biol Chem. 2001 Jun 15;276(24):21489-99. Epub 2001 Mar 21.PMID: 11262390 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake.

    Navarro M, Rodriquez de Fonseca F, Alvarez E, Chowen JA, Zueco JA, Gomez R, Eng J, Blázquez E.

    J Neurochem. 1996 Nov;67(5):1982-91.PMID: 8863504 [PubMed - indexed for MEDLINE]Related articles

    12.

    Glucagon and glucagon-like peptide receptors as drug targets.

    Estall JL, Drucker DJ.

    Curr Pharm Des. 2006;12(14):1731-50. Review.PMID: 16712485 [PubMed - indexed for MEDLINE]Related articles

    13.

    Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist.

    Pan CQ, Buxton JM, Yung SL, Tom I, Yang L, Chen H, MacDougall M, Bell A, Claus TH, Clairmont KB, Whelan JP.

    J Biol Chem. 2006 May 5;281(18):12506-15. Epub 2006 Feb 27.PMID: 16505481 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo.

    Xiao Q, Giguere J, Parisien M, Jeng W, St-Pierre SA, Brubaker PL, Wheeler MB.

    Biochemistry. 2001 Mar 6;40(9):2860-9.PMID: 11258897 [PubMed - indexed for MEDLINE]Related articles

    15.

    A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.

    Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, Gidda J, Findeisen H, Bruemmer D, Drucker DJ, Chaudhary N, Holland J, Hembree J, Abplanalp W, Grant E, Ruehl J, Wilson H, Kirchner H, Lockie SH, Hofmann S, Woods SC, Nogueiras R, Pfluger PT, Perez-Tilve D, DiMarchi R, Tschöp MH.

    Nat Chem Biol. 2009 Oct;5(10):749-57. Epub 2009 Jul 13.PMID: 19597507 [PubMed - indexed for MEDLINE]Related articles

    16.

    Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes.

    Claus TH, Pan CQ, Buxton JM, Yang L, Reynolds JC, Barucci N, Burns M, Ortiz AA, Roczniak S, Livingston JN, Clairmont KB, Whelan JP.

    J Endocrinol. 2007 Feb;192(2):371-80.PMID: 17283237 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice.

    Flock G, Baggio LL, Longuet C, Drucker DJ.

    Diabetes. 2007 Dec;56(12):3006-13. Epub 2007 Aug 23.PMID: 17717280 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor.

    Cani PD, Knauf C, Iglesias MA, Drucker DJ, Delzenne NM, Burcelin R.

    Diabetes. 2006 May;55(5):1484-90.PMID: 16644709 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Boc5, a non-peptidic glucagon-like Peptide-1 receptor agonist, invokes sustained glycemic control and weight loss in diabetic mice.

    Su H, He M, Li H, Liu Q, Wang J, Wang Y, Gao W, Zhou L, Liao J, Young AA, Wang MW.

    PLoS One. 2008 Aug 6;3(8):e2892.PMID: 18682834 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness.

    Beinborn M, Worrall CI, McBride EW, Kopin AS.

    Regul Pept. 2005 Aug 15;130(1-2):1-6.PMID: 15975668 [PubMed - indexed for MEDLINE]Related articles

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity